Rhumbline Advisers Tyme Technologies, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 05, 2021	SELL	$1.14 - $1.87 $110,415 - $181,120	-96,856 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$1.34 - $3.53 $368 - $970	275 Added 0.28%	96,856 $172,000
Q4 2020 Feb 10, 2021	BUY	$0.87 - $1.26 $4,437 - $6,426	5,100 Added 5.57%	96,581 $118,000
Q3 2020 Nov 12, 2020	SELL	$0.93 - $1.35 $10,369 - $15,052	-11,150 Reduced 10.86%	91,481 $90,000
Q2 2020 Aug 13, 2020	BUY	$0.97 - $1.7 $5,596 - $9,809	5,770 Added 5.96%	102,631 $136,000
Q4 2019 Feb 05, 2020	SELL	$1.0 - $1.49 $888 - $1,323	-888 Reduced 0.91%	96,861 $136,000
Q3 2019 Oct 23, 2019	SELL	$0.97 - $1.77 $1,311 - $2,393	-1,352 Reduced 1.36%	97,749 $116,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $25,304 - $49,818	-26,359 Reduced 21.01%	99,101 $121,000
Q1 2019 May 01, 2019	SELL	$1.76 - $3.73 $3,537 - $7,497	-2,010 Reduced 1.58%	125,460 $221,000
Q4 2018 Jan 31, 2019	BUY	$2.01 - $4.21 $189,758 - $397,453	94,407 Added 285.54%	127,470 $470,000
Q3 2018 Nov 07, 2018	SELL	$2.18 - $3.44 $4,091 - $6,456	-1,877 Reduced 5.37%	33,063 $92,000
Q2 2018 Aug 06, 2018	BUY	$2.05 - $4.09 $71,627 - $142,904	34,940 New	34,940 $110,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.